Pharmacovigilence
Monitoring of Adverse Drug Reactions is particularly crucial for drug safety in the rapidly developing field of immuno-oncology, especially as the true incidence of ADRs may not yet be known, new ADRs may emerge and long-term effects are also as yet unknown. Reporting via the MHRA yellow card scheme and collaborative sharing of experience through the IOCN will facilitate accurate reporting and increase national awareness.